Zacks Research Comments on Thermo Fisher Scientific Inc.'s Q3 2025 Earnings (NYSE:TMO)

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Stock analysts at Zacks Research boosted their Q3 2025 earnings estimates for shares of Thermo Fisher Scientific in a report released on Thursday, May 16th. Zacks Research analyst R. Anand now forecasts that the medical research company will post earnings of $6.53 per share for the quarter, up from their previous forecast of $6.52. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $21.65 per share.

TMO has been the subject of a number of other research reports. Royal Bank of Canada raised their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an "outperform" rating in a research note on Thursday, February 1st. Citigroup assumed coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a "neutral" rating and a $620.00 price objective for the company. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating on the stock in a research note on Thursday, April 25th. HSBC upped their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a "buy" rating in a report on Tuesday, April 30th. Finally, Barclays boosted their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an "equal weight" rating in a research report on Thursday, April 25th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $607.35.

Thermo Fisher Scientific Stock Performance

TMO traded down $1.85 during trading hours on Friday, reaching $595.30. The company's stock had a trading volume of 1,394,082 shares, compared to its average volume of 1,528,367. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The company's 50-day moving average is $576.79 and its 200-day moving average is $540.89. Thermo Fisher Scientific has a 52 week low of $415.60 and a 52 week high of $603.82. The firm has a market cap of $227.24 billion, a PE ratio of 38.30, a price-to-earnings-growth ratio of 2.48 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts' consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The firm had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Northwest Financial Advisors bought a new position in Thermo Fisher Scientific during the 4th quarter worth $29,000. True Wealth Design LLC raised its position in shares of Thermo Fisher Scientific by 1,275.0% during the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company's stock worth $29,000 after acquiring an additional 51 shares during the last quarter. LifeSteps Financial Inc. bought a new stake in Thermo Fisher Scientific in the first quarter valued at approximately $31,000. Headlands Technologies LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at approximately $32,000. Finally, Pineridge Advisors LLC acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $39,000. Institutional investors own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company's stock, valued at $74,039,491.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the company's stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares of the company's stock, valued at approximately $7,430,359.02. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. Insiders have sold 32,000 shares of company stock valued at $18,486,980 over the last ninety days. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a dividend of $0.39 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.35. Thermo Fisher Scientific's payout ratio is 10.01%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.